Calculation of costs of medicaments, medical material, therapy and social service in patients with diabetic foot syndrome;Kalkulace nákladů na léky, zdravotní materiál, některé vybrané léčebné výkony a služby sociální oblasti u pacientů se syndromem diabetická noha

Vnitrni Lekarstvi

Volumn 49, Issue 6, 2003, Pages 457-464

  Brunerová, Ludmila ^a   Andel M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Costs; Diabetic foot syndrom; Primary, secondary and tertiary prevention

Indexed keywords

ANTIINFECTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIMICROBIAL THERAPY; ARTICLE; CALCULATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; CZECH REPUBLIC; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; HEALTH CARE COST; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIMARY PREVENTION; SECONDARY PREVENTION; SOCIAL WORK;

AGED; CZECH REPUBLIC; DIABETES MELLITUS; DIABETIC FOOT; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE;

EID: 0038105508     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Appelquist, J. et al.: Diabetic Foot Ulcers in a Multidisciplinary Setting. An Economic Analysis of Primary Healing and Healing with Amputation., J. Int. Med., 1994, 235: 463-471
2. Ahroni, J. et al.: Diabetic Foot Ulcer Healing: Extrinsic vs. Intrinsic Factors, Wounds, 5, 1993, 245-255
3. Bartoš, V., Pelikánová, T.: Praktická diabetologie. Praha, Maxdorf 1996, 62
4. Bartoš, V., Záhumenský, E., Jirkovská, A. et al.: Standardy péče o diabetickou nohu, Vnitř. Lék. 42, 1996, 1: 54-56
5. Bild, D. et al.: Lower Extremity Amputation in People with Diabetes, Epidemiology and Prevention. Diab. Care, 12, 1989, 24-31
6. Blackman, J. et al.: Clinical Evaluation of the Semi-permeable Polymeric Membrane Dressing for the Treatment of the Chronic Diabetic Foot Ulcers. Diab. Care 17, 1994, 322-325
7. Boulton, J.: Lowering the risk of neuropathy, foot ulcers and amputation. Diab. Med. 1998, 15, suppl. 4: 57-59
8. Brunerová, L., Anděl, M.: Náklady na syndrom diabetická nohy v mezinárodním srovnání. DMEV, 2002, 3: 153-156
9. Campbell, P. K.: Clinical update on pentoxifylline therapy for diabetes induced peripheral vascular disease. Ann. Pharmacother. 1993, 27 (9): 1099-1105
10. Curb, J. K.: Effect of diuretic based antihypertenzive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: JAMA 1996, 276: 1886-1892
11. Čechurová, D. et al.: Ekonomický pohled na léčbu syndromu diabetická noha, Diabetol. Metabol. Endokr. Výživa. 2001, 4: 10
12. Česká diabetologická společnost: Standardy péče o diabetes mellitus 1. Typu. DMEV, 1992, 2, 100-103
13. Česká diabetologická společnost: Doporučený postup pro intenzifikovanou inzulinovou terapii u diabetiků 1. typu. DMEV, 1, 1999, 40-41
14. Česká diabetologická společnost: Standardy péče o diabetes 2. typu. Prakt. Lék., 77, 1997, 401-403
15. Češka, R. et al.: Doporučení pro diagnostiku a léčbu hyperlipoproteinémií. Cas. Lék. čes., 1997, 136, 257-261
16. Defronzo, R. et al.: DCCT: An Implications for the Diabetic Foot, J. Foot. Ankle Surg., 1994, 33, 531-545
17. Faglia, E. et al.: Feasibility and effectiveness of peripheral percutaneous transluminal balloon angioplasty in diabetic subjects with foot ulcers. Diab. Care 1996, 19 (11): 1261-1264
18. Foster, A. et al.: Comparing Two Dressings in the Treatment of Diabetic Foot Ulcers. J. Wound. Care, 3, 1994, 224-228
19. Gayle E.: Diabetic Foot Care, Financial Implications and Practice Guidelines. Diab. Care, 1992, 15: 29-31
20. Gray, A. et al.: Cost Effectiveness of an Intensive Blood Glucose Control Policy in Patients with Type II. Diabetes (UKPDS). BMJ 2000, 320: 1373-1378
21. Holzer, S. E., Camerota, A. et al.: Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin. Ther., 1998, 20: 169-181
22. HOPE group: Effects of an ACE inhibitor ramipril on cardiovascular events in high risk patients. N. Eng. J. Med., 2000, 145-153
23. Horký, K. et al.: Standardy diagnostiky a léčby u arteriální hypertenze. Prakt. Lék., 1997, 77, 301-305
24. Jirkovská, A.: Diabetická noha. In: Praktická diabetologie, ed. Bartoš, V., Pelikánová T., Praha, Maxdorf, 200, 305-325
25. Jirkovská, A.: Syndrom diabetická nohy - jedna z nejzávažnějších diabetu. Vnitř. Lék. 47, 2001, 5: 311-314
26. Lacigová, S. et al.: Efekt hydrokoloidního krytí granuflex v léčbě diabetické nohy. Sestra 4, 1996, 14-16
27. O'Brien, J. et al.: Direct Medical Costs of Complications Resulting From Type 2 Diabetes in the USA. Diab. Care 1998, 21: 1122-1128
28. O'Connor, P. et al.: Care of Adults with Type 2 Diabetes Mellitus, a Review of the Evidence. J. Farm. Pract., 1998, 47, 13-32
29. PPP group: Primary prevention project: Lancet 2001, 357: 89-95
30. Pedersen, T. R. et al.: 4S: Effect of simvastatin on ischemic signs and symptoms in the SSSS. Am. J. Cardiol 1998, 81: 333-335
31. Ramani, A. et al.: Hemorheologic approach in the treatment of diabetic foot ulcers. Angiology 1993, 44 (8): 623-626
32. Rosolová, H.: Patogeneze a léčba hypertenze u diabetiků. Cor et Vasa, 1995, 37, 44-51
33. Ruhnau, K. et al.: Effects of 3-week Oral Treatment with Thioctacid Acid in Symptomatic Diabetic Polyneuropathy. Diab. Med., 1999, 16, 1040-1043
34. Rušavý, Z. et al.: Diabetická noha. Diagnostika a terapie v praxi, Galén 1998: 83-91
35. STOP 2 Hypertension group: Swedish trial in old patients with hypertension. Lancet 1999, 354: 1751-1756
36. UKPDS group: Tight blood pressure control and risk of macro and microvascular complications in type 2 diabetes. UKPDS 38. Brit. Med. J. 1998, 317: 703-713
37. UKPDS group: Efficacy of atenolol and captopril in reducing risk of macro and microvascular complications in type 2 diabetes. UKPDS 39. Brit. Med. J., 1998, 317: 713-720
38. UKPDS group: Intensive blood glucose control with SU or insulin compared with conventional treatment and risk of complications in patients with type 21 diabetes UKPDS 33. Lancet 1998, 12 (352): 837-853
39. Va Hit group: Va-HIT: the Va HDL intervention trial. Am. Heart J. 1999, 137: 555-574, Circulation 1999, 99: 2486-2491
40. Va Hit group: Va-HIT: the Va HDL intervention trial. Am. Heart J. 1999, 137: 555-574, Circulation 1999, 99: 2486-2491
41. Vítovec, J. et al.: Vliv ramiprilu na metabolické, renální a srdeční funkce u hypertenze a diabetes mellitus. Vnitř. Lék. 1998, 44: 332-335
42. Young, M. et al.: The Diabetic foot: management and aethiopatogenesis. Diab. Met. Rew., 1993, 9: 109-127
43. WHO/IDF Europe: Diab. Care and research in Europe, St. Vincent Declaration. Diab. Med. 7, 1990, 360
44. Záhumenský E. et al.: Nové aspekty farmakologické a obecně profylaktické péče o diabetickou nohu. Vnitř. Lék., 1995, 41, 531-534